EUCTR2016-000891-54-SE
Active, not recruiting
Phase 1
Effects of enhanced dopaminergic neurotransmission on working memory training efficiency in the healthy elderly - A prospective, single center, randomized, double blind, placebo controlled, parallel group, phase II trial - REBOOT-II
Aging Research Center, Karolinska Institutet and Stockholm University0 sites70 target enrollmentOctober 5, 2016
Conditionso medical condition is under investigation. The project investigates normal age-related decline in intellectual abilities.Therapeutic area: Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04]
DrugsMadopark Quick
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- o medical condition is under investigation. The project investigates normal age-related decline in intellectual abilities.
- Sponsor
- Aging Research Center, Karolinska Institutet and Stockholm University
- Enrollment
- 70
- Status
- Active, not recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Mini\-Mental State Examination score \>26;
- •Aged between 65 and 75 years;
- •Absence of medical or psychiatric conditions specified in the exclusion criteria;
- •Signed informed consent;
- •Right handedness;
- •Fluent Swedish;
- •Absence of colorblindness;
- •No previous participation in studies of similar design;
- •No trauma to the head with loss of consciousness for more than 10 min;
- •No history of brain injuries;
Exclusion Criteria
- •Glaucoma (any history);
- •Any history of serious heart disease (myocardial infarction, arrhythmia, atrioventricular block);
- •Serious problems with heart and blood vessels, systolic/diastolic blood pressure \< 100/50 or \>160/95; Heart Failure: NYHA \> IB; Chronic Venous Disease CEAP \> C2\);
- •Severe pulmonary diseases;
- •Type I diabetes;
- •Recent history (5 years) of stomach and duodenum ulcers;
- •Liver diseases (e.g. hepatitis, liver failure);
- •Bleeding of the stomach or intestines;
- •Kidney diseases;
- •Serious urination problems;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Pharmaceutical enhancement of complex problem-solving in healthy adultsCognitive enhancementMental Health - Studies of normal psychology, cognitive function and behaviourNeurological - Studies of the normal brain and nervous systemACTRN12617001544369The University of Melbourne32
Completed
Not Applicable
The effects of increased levels of dopamine on the activation in the dopaminergic system.n.v.t.10009841NL-OMON33408niversiteit Maastricht20
Recruiting
Phase 2
The effect of dopamine on the appropriate time of urination in oliguric patientsoliguria.Anuria and oliguriaIRCT2017011513366N6Vice Chancellor for Research,Arak University of Medical Sciences120
Active, not recruiting
Phase 1
Effet de la stimulation dopaminergique continue par pompe à apomorphine sur les fluctuations cognitives et psychiques des patients parkinsoniens: étude clinique et métabolique cérébrale par TEP au 18FDG - APO TEPL’objectif thérapeutique principal dans la maladie de Parkinson est de contrôler les fluctuations motrices. Cependant des fluctuations non motrices (FNM) sont fréquemment observées et semblent corrélées à la sévérité de la maladie. La stabilité dans le temps de l’efficacité du traitement dopaminergique est le moyen le plus pertinent pour améliorer les fluctuations tant motrices que non motrices.MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson'sEUCTR2008-006045-10-FRCHU de Rennes30
Completed
Not Applicable
Dopaminergic neurotransmission and cognitive deterioration in velocardiofacial syndromeNL-OMON33641Medisch Universitair Ziekenhuis Maastricht44